Fri, 27/08/2021 | News

Webinar video now available - What’s next for Australia’s COVID-19 vaccine program?

Moderna COVID-19 vaccine and model predictions  

In Australia and globally we continue to face new challenges in the prevention of COVID-19. This webinar, held on Thursday 26 August 2021, discussed what’s next for Australia’s COVID-19 vaccine program as we aim to emerge from the pandemic.  

Watch the recording of this webinar to:

  • learn about the Moderna COVID-19 vaccine that will roll out in Australia from September 2021, with an overview from Dr Randall Hyer, Senior Vice President, Moderna Therapeutics, Inc
  • be updated on COVID-19 vaccine effectiveness and protection against the Delta variant
  • gain a deeper understanding of modeling of the COVID-19 vaccine impact that is informing Australia’s approach to emerging from the pandemic.

 
Speakers:

Portrait of Dr Randall HyerDr Randall Hyer
Senior Vice President, Moderna Therapeutics, Inc

Dr Randall Hyer has over three decades of experience in medicine and public health in both the public and private sectors. After graduating with distinction from the US Naval Academy, he studied at Duke Medical School and then earned the PhD in molecular biology from Oxford University. He then spent 13 months on the “ice” in Antarctica as the Station Physician for the winter. Dr Hyer then shifted to public health and vaccines, serving four years at the World Health Organization as a medical officer responding to outbreaks and emergencies, including anthrax, Ebola, SARS, avian influenza, as well as tsunamis and earthquakes.

In response to the need for effective communication, Randy co-authored a popular WHO handbook on risk and crisis communication during public health emergencies. In industry, Randy’s experience covers vaccines, biologics, biosimilars and small molecule development. He was pivotal to the 2017 approval of a two-dose adult hepatitis B vaccine (HEPLISAV-B), the first FDA-approved vaccine with a truly novel adjuvant.

Beyond development, his responsibilities have included directing vaccine and pharmaceutical safety programs, overseeing vaccine clinical operations and biometrics functions, engaging medical scientists and policy-makers, and managing crises. Randy’s perspectives and contributions span his residing in eight and travelling to 100 plus countries in diverse roles across the public and private sectors.

Portrait of Professor Jodie McVernonProfessor Jodie McVernon
Director of Epidemiology, Peter Doherty Institute for Infection and Immunity

Professor Jodie McVernon is a public health physician and epidemiologist. She has extensive expertise in clinical vaccine trials, epidemiological studies and mathematical modelling of infectious diseases, gained in Oxford, London and Melbourne.

For the past 15 years, she has been building capacity in infectious diseases modelling in Australia to inform immunisation and pandemic preparedness policy. She has led nationally distributed networks of modellers informing responses to the 2009 H1N1 influenza pandemic and the current COVID-19 pandemic.